Title: “Cancer vaccine reduces melanoma risk 49% after five years”
Authors: Sophia Navarre, Maki N. Ishibashi, Achuth Nair, Ivan Reyes-Torres, Meriem Belabed, Laszlo Halasz, Matthew D. Park, Raphaël Mattiuz, Merouane Ounadjela, Gertrude Gunset, Jorge Mansilla-Soto, Judith Feucht, Annalisa Cabriolu, Jessica Le Berichel, Alexander Birbrair, Justin Eyquem, Brian D. Brown, Miriam Merad, Michel Sadelain & Jalal Ahmed
Background
CAR T cell therapy has transformed the treatment of several blood cancers, especially CD19-positive B cell malignancies, but its success in solid tumors has remained limited. One major challenge is that CAR T cells often fail to expand and persist inside solid tumor microenvironments. Another problem is safety: many solid tumor antigens are also present on normal tissues, creating a risk of on-target, off-tumor toxicity if CAR T cells are given at higher doses. A new preclinical study published in Nature Cancer investigated whether local tumor irradiation could help overcome these barriers by selectively increasing CAR T cell activity at tumor sites without increasing damage to nearby normal tissue.
Methods
The investigators used syngeneic mouse models of extensive metastatic lung adenocarcinoma and melanoma. The main lung cancer model was based on KrasG12D;Trp53−/− KP tumors, which resemble important immune features of human non-small cell lung cancer. Tumor-bearing mice received CAR T cells after tumors were already established, creating a difficult treatment setting that better reflects advanced solid cancer.
The study tested thoracic radiotherapy, mainly a single 8 Gy dose, before CAR T cell infusion. The researchers compared irradiated and non-irradiated tumors and evaluated tumor burden, CAR T cell persistence, survival, immune-cell composition, dendritic-cell function, and toxicity. CAR T cells were directed against model and endogenous tumor antigens, including human CD19, GD2, and EpCAM.
Study Design
Mice were inoculated with lung tumors through tail-vein injection. In the KP lung adenocarcinoma model, CAR T cell therapy was administered when tumors were advanced, approximately 28 days after tumor injection. At this point, tumors measured about 2.2 mm² on average and occupied around 20% of the lung area. Untreated mice usually reached humane endpoints within the next 2 weeks, confirming the aggressive disease setting.
In key experiments, mice were randomized to receive either 8 Gy thoracic radiotherapy or no irradiation. They then underwent lymphodepletion with cyclophosphamide followed by adoptive transfer of syngeneic CAR T cells. CAR T doses included 4 × 10⁶ CAR T cells per mouse in several tissue-analysis experiments and 2.5 × 10⁶ CAR T cells per mouse in survival and bioluminescence-tracking studies.
The team also tested whether lower-dose irradiation could produce the same effect. They compared 8 Gy thoracic irradiation with 2 Gy thoracic irradiation and 2 Gy total-body irradiation. Additional experiments depleted dendritic cells or used Batf3-deficient mice lacking DC1 cells to determine whether dendritic cells were necessary for the observed treatment benefit.
Results
The study found that 8 Gy tumor irradiation significantly improved CAR T cell activity against established lung tumors. In vitro, 8 Gy irradiation sensitized target-positive KP tumor cells to CAR T cell cytotoxicity, with no additional benefit from higher radiation doses. In vivo, irradiated mice had significantly lower tumor burden after CAR T cell therapy compared with non-irradiated controls.
Survival also improved when CAR T cells targeted irradiated antigen-positive tumors. This benefit required both radiation and CAR target recognition. CAR T cells directed against irradiated target-positive tumors improved survival, while the same effect was not seen when target recognition was absent.
Bioluminescence imaging showed that CAR T cells alone and radiotherapy alone could temporarily reduce tumor signal, but only the combination of irradiation followed by CAR T cell therapy produced a sustained reduction in tumor bioluminescence. In one experiment, this translated into improved survival with a reported P value of 0.0259.
A key finding was that irradiation increased CAR T cell persistence inside tumors. Nine days after CAR T transfer, CD8+ CAR T cells were approximately 8-fold higher and CD4+ CAR T cells approximately 2-fold higher in irradiated tumor-bearing lungs compared with non-irradiated lungs. Importantly, this was not simply due to better early homing, because CAR T cell numbers were similar 3 days after injection. Instead, the data suggested that irradiation supported continued CAR T cell expansion or survival within the tumor site.
RNA sequencing showed broad transcriptional changes in CAR T cells from irradiated tumors. In CD8+ CAR T cells, 522 genes were differentially expressed, including 71 enriched genes and 451 genes with lower expression. Pathways related to mitochondrial activity, oxidative phosphorylation, electron transport, cell cycle, and IL-2 signaling were enriched. CAR T cells in irradiated tumors also showed higher expression of cytotoxicity-related genes, including Prf1, Gzma, Gzmb, and Rab27a. Intratumoral CAR T cell density was about 5-fold greater after irradiation.
The researchers also observed that CAR T cells in irradiated tumors maintained lower surface expression of several checkpoint and coinhibitory receptors compared with CAR T cells in non-irradiated tumors. This suggests that irradiation changed the immune context in a way that supported a more functional CAR T cell state.
Key Findings
One of the most important mechanistic findings involved dendritic cells. The study showed that dendritic cells were required for sustained CAR T cell persistence after irradiation. When dendritic cells were depleted, the enhanced CAR T cell persistence seen with irradiation was lost. Tumors eventually relapsed despite initial treatment effects, showing that direct tumor radiosensitization alone was not enough for durable tumor control.
The investigators identified a process called antigen dressing. After tumor irradiation, dendritic cells acquired tumor-derived surface antigens through a trogocytosis-like process. These antigen-dressed dendritic cells could then activate and expand CAR T cells through the chimeric antigen receptor itself. This is important because CAR T cells are usually thought to recognize antigens directly on tumor cells. Here, dendritic cells served as a secondary platform for CAR T cell stimulation.
The study also showed that not all antigen-presenting cells had the same effect. Macrophages could acquire antigen but did not expand CAR T cells in the same way. This suggests that dendritic cells provide additional supportive signals beyond antigen display.
Another key finding was selectivity. Irradiation increased CAR T cell numbers inside tumors but not in adjacent normal lung tissue, even when the normal tissue expressed the target antigen. This was tested using CAR T cells against endogenous antigens such as GD2 and EpCAM. EpCAM was present on a much larger fraction of normal lung stromal cells than GD2, yet irradiation did not increase CAR T accumulation in normal lung parenchyma.
In EpCAM-targeted experiments, irradiated mice treated with EpCAM CAR T cells showed sustained tumor control and survival curves similar to mice treated with CAR T cells against the more tumor-restricted hCD19 target. Importantly, this improved efficacy was not associated with increased weight loss or acute lethality at the tested dose.
Lower-dose approaches were less effective. A 2 Gy thoracic dose did not increase CAR T cell persistence to the same extent as 8 Gy. A 2 Gy total-body irradiation dose transiently increased CAR T persistence but did not improve survival. This suggests that focal, higher-dose tumor irradiation may be more relevant for radioresistant solid tumors such as lung adenocarcinoma and melanoma.
Key Takeaway Messages
A single 8 Gy dose of tumor irradiation enhanced CAR T cell persistence and efficacy in preclinical models of lung metastases.
The effect depended on dendritic cells, especially their ability to acquire tumor antigens and stimulate CAR T cells through the CAR receptor.
Irradiation increased CAR T cells inside tumors but did not proportionally increase CAR T cells in adjacent normal lung tissue.
The combination improved activity against both model antigens and clinically relevant endogenous antigens such as GD2 and EpCAM.
Direct tumor radiosensitization was not enough for durable control; sustained CAR T cell activity required dendritic-cell-mediated immune support.
These findings remain preclinical and require further study before translation into clinical practice.
Conclusion
This study provides a strong mechanistic rationale for combining radiotherapy with CAR T cell therapy in solid tumors. The data suggest that tumor irradiation does more than damage cancer cells. It reshapes the tumor immune microenvironment by enabling dendritic cells to acquire tumor antigens and support CAR T cell expansion at the tumor site.
The most clinically relevant message is the possibility of widening the therapeutic window. In solid tumors, CAR T cell therapy is often limited by poor persistence and safety concerns when targets are shared with normal tissues. In this study, irradiation improved tumor-localized CAR T cell activity without increasing CAR T accumulation in nearby normal lung tissue or causing clear added toxicity in the tested models.
Although these findings are not yet ready to guide patient treatment, they offer a practical direction for future research. Optimized hypofractionated radiotherapy regimens may help convert solid tumors into more favorable sites for CAR T cell activity. Future clinical studies will need to define the best radiation dose, timing, tumor types, target antigens, and safety monitoring strategies. For now, the study adds an important piece to the broader effort to make CAR T cell therapy effective beyond hematologic cancers.
Discover more articles like this on OncoDaily